Hepatitis B re-activation with rituximab therapy: Treat the patient not the disease

Liver International

Volumn 31, Issue 3, 2011, Pages 277-279

  Zachou, Kalliopi ^a   Dalekos, George N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; RITUXIMAB; TENOFOVIR; VIRUS DNA;

ANTIGEN DETECTION; CANCER CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DNA DETERMINATION; DRUG SAFETY; EDITORIAL; ETHNICITY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATITIS B; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; JAPANESE; MEDICAL SPECIALIST; META ANALYSIS (TOPIC); MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SAMPLE SIZE; SEROLOGY; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; MASS SCREENING; VIRUS ACTIVATION;

EID: 79551511664     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02452.x     Document Type: Editorial

References (22)

1. Gartlehner G, Thieda P, Morgan LC, et al. Drug Class Review: Targeted Immune Modulators: Final Report Update 2. Portland, Oregon, USA: Oregon Health and Science University, 2009; 1-210 [Internet].
2. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies-historical and future perspectives. Haematologica 2010; 95: 135-43.
3. Selewski DT, Shah GV, Mody RJ, Rajdev PA, Mukherji SK. Rituximab (Rituxan). Am J Neuroradiol 2010; 31: 1178-80.
4. Gürcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10-25.
5. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2010. DOI: DOI: 10.1093/annonc/mdq583; PMID: 21115603 [Epub ahead of print].
6. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004; 24: 540-6.
7. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28: 28-38.
8. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. AASLD Practice Guidelines. Hepatology 2009; 50: 1-36.
10. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
11. EASL. Clinical Practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
12. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus development conference statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-10.
13. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-53.
14. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-65.
15. Méndez-Navarro J, Corey KE, Zheng H, et al. Hepatitis B screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy. Liver Int 2011; 31: 330-9.
16. Watanabe M, Shibuya A, Tsunoda Y, et al. Reappearance of hepatitis B virus (HBV) following therapy with rituximab for lymphoma is not rare in Japanese patients with past HBV infection. Liver Int 2011; 31: 340-7.
17. Pei S-N, Chen C-H, Lee C-M, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-62.
18. Yeo W, Chan TC, Leung N, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
19. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
20. Ferraro D, Pizzillo P, Di Marco V, et al. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int 2009; 29: 1171-7.
21. Georgiadou SP, Dalekos GN. Which level of immunosuppression is harmful for occult hepatitis B virus infection?: 'A million dollar' answer. Liver Int 2009; 29: 1127-8.
22. Georgiadou SP, Zachou K, Liaskos C, et al. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 2009; 29: 434-42.